Market Overview

UPDATE: Canaccord Genuity Lowers PT on Allergan on Disappointments Hitting Sentiment


In a report published Tuesday, Canaccord Genuity analyst Randall Stanicky lowered the price target on Allergan (NYSE: AGN) from $111 to $98 and reiterated a Hold rating on the company.

In the report, Canaccord Genuity commented, "With yesterday’s 12% RESTASIS driven sell-off, AGN shares are down 29% from mid-April year highs on the back of three disappointments that have also hit sentiment including (1) the LEVADEX complete response letter; (2) the DARPin set-back; and now (3) the RESTASIS draft FDA guidance that drove several recent downgrades. While our initial reaction is to go the other way and upgrade AGN as a RESTASIS generic now feels fully priced in and the stock is at trough valuation levels, we still lack catalysts needed for a sustained reversal."

Allergan closed Monday at $81.99.

Latest Ratings for AGN

Nov 2019DowngradesBuyNeutral
Sep 2019MaintainsBuy
Aug 2019DowngradesBuyNeutral

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Randall StanickyAnalyst Color Price Target Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!

Latest Ratings

ROSTMKM PartnersMaintains121.0
BJDeutsche BankMaintains27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Lennar Rises On Upbeat Profit, Barnes & Noble Tumbles

Why Federal Reserve Tapering is At Least 1.5 Years Away